fibroblast
play
pivot
role
cardiac
remodel
develop
heart
failur
deposit
extracellular
matrix
ecm
protein
also
affect
cardiomyocyt
growth
function
reninangiotensin
system
ra
key
regul
cardiovascular
system
health
diseas
mani
effect
involv
cardiac
fibroblast
level
angiotensin
ii
ang
ii
main
effector
molecul
ra
elev
fail
heart
substanti
bodi
evid
indic
peptid
contribut
chang
cardiac
structur
function
ultim
lead
progress
worsen
heart
failur
pathway
involv
angiotensin
convert
enzym
capac
break
ang
ii
gener
angiotensin
ang
heptapeptid
contrast
ang
ii
cardioprotect
antiremodel
effect
mani
ang
action
involv
cardiac
fibroblast
inform
indic
reduc
collagen
product
also
may
protect
cardiac
hypertrophi
report
describ
effect
ang
appear
relev
cardiac
remodel
heart
failur
explor
potenti
therapeut
strategi
design
increas
activ
ang
level
treat
condit
despit
import
advanc
treatment
heart
failur
past
sever
decad
morbid
mortal
patient
condit
remain
unaccept
high
level
remodel
heart
occur
respons
injuri
andor
increas
wall
stress
play
key
role
progress
deterior
cardiac
function
lead
heart
failur
thu
new
therapi
inhibit
remodel
would
expect
improv
outcom
remodel
character
cardiac
hypertrophi
dilat
well
conform
chang
shape
heart
cardiac
fibrosi
develop
site
distant
local
injuri
eg
segment
noninfarct
myocardium
patient
ischem
cardiomyopathi
occur
remodel
process
advers
affect
systol
diastol
function
heart
promot
cardiac
arrhythmia
deposit
extracellular
matrix
ecm
depend
primarili
cardiac
fibroblast
produc
mani
interstiti
protein
heart
releas
enzym
matrix
metalloproteinas
tissu
inhibitor
metalloproteinas
regul
balanc
ecm
product
breakdown
also
evid
cardiac
fibroblast
releas
growth
factor
act
paracrin
manner
stimul
cardiomyocyt
hypertrophi
addit
help
maintain
cardiovascular
homeostasi
influenc
salt
water
regul
vascular
tone
ra
play
import
role
maladapt
cardiac
remodel
mechan
ra
contribut
remodel
process
includ
indirect
effect
lead
increas
load
heart
interact
neurohormon
system
direct
effect
cardiac
cell
angiotensin
ii
ang
ii
main
effector
molecul
ra
act
predominantli
type
receptor
activ
cardiac
fibroblast
function
increas
amount
ecm
heart
although
ang
ii
shown
stimul
cardiomyocyt
hypertrophi
activ
appear
mainli
indirect
sinc
applic
peptid
cultur
cardiomyocyt
littl
effect
cell
growth
synthesi
protein
cultur
media
taken
adult
cardiac
fibroblast
howev
stimul
cardiomyocyt
hypertrophi
effect
significantli
enhanc
ang
ii
activ
cardiac
fibroblast
receptor
observ
consist
evid
receptor
densiti
substanti
greater
cardiac
fibroblast
cardiomyocyt
moreov
increas
receptor
occur
heart
remodel
involv
predominantli
nonmyocyt
thu
cardiac
fibroblast
appear
predomin
target
ra
cardiac
remodel
local
tissuebas
cardiac
ra
regul
independ
system
circulatori
ra
activ
central
remodel
process
cell
within
heart
gener
compon
ra
case
renin
activ
extract
coronari
circul
ang
ii
level
receptor
densiti
increas
myocardium
remodel
heart
moreov
result
studi
perform
experiment
anim
model
clinic
trial
human
patient
provid
unequivoc
evid
strategi
design
block
ra
activ
favor
influenc
cardiac
remodel
improv
outcom
includ
increas
surviv
ang
ii
receptor
involv
physiolog
pathophysiolog
effect
ra
addit
pathway
within
system
relev
health
diseas
known
exist
homologu
angiotensin
convert
enzym
ace
term
angiotensin
convert
enzym
report
independ
two
group
approxim
amino
acid
sequenc
similar
ace
enzym
exist
type
integr
membranebound
glycoprotein
amino
acid
includ
aminotermin
signal
peptid
catalyt
ectodomain
transmembran
domain
carboxyltermin
cytoplasm
domain
singl
metalloproteas
zinc
bind
motif
locat
ectodomain
function
carboxymonopeptidas
shown
figur
catalyz
convers
ang
angiotensin
turn
convert
ang
peptidas
hydrolyz
ang
ii
ang
high
catalyt
affin
thu
wherea
ace
gener
ang
ii
reduc
ang
ii
level
produc
ang
known
substrat
includ
physiolog
activ
peptid
desarg
bradykinin
dynorphin
cleavag
carboxyltermin
amino
acid
ang
ii
result
format
ang
heptapeptid
vasodilatori
cardioprotect
properti
also
report
counteract
effect
ang
ii
promot
advers
cardiac
remodel
figur
assess
potenti
role
ang
cardiac
remodel
measur
effect
peptid
select
function
cultur
adult
rat
cardiac
fibroblast
arcf
pretreat
arcf
ang
inhibit
ang
ii
stimul
h
prolin
incorpor
suggest
ang
might
reduc
fibrou
tissu
deposit
particularli
situat
ang
ii
stimul
involv
stimul
ang
also
reduc
h
prolin
incorpor
compar
unstimul
cell
pretreat
arcf
ang
significantli
reduc
ang
ii
stimul
increas
leukemia
inhibitori
factor
mrna
suggest
peptid
might
inhibit
synthesi
autocrin
paracrin
growth
factor
cardiac
fibroblast
explor
possibl
cardiomyocyt
expos
ang
ii
ang
ang
ii
ang
pretreat
angiotensin
peptid
alon
induc
cardiomyocyt
hypertrophi
assess
h
leucin
incorpor
atrial
natriuret
peptid
synthesi
exposur
cardiomyocyt
arcf
cultur
media
induc
hypertroph
respons
compar
mock
cultur
media
contact
fibroblast
increas
significantli
arcf
stimul
ang
ii
increas
howev
inhibit
pretreat
arcf
ang
overal
find
suggest
ang
may
play
import
counterregulatori
role
cardiac
remodel
inhibit
cardiac
fibroblast
ecm
synthesi
releas
hypertroph
growth
factor
pathway
ang
initi
potenti
favor
antiremodel
effect
fulli
elucid
investig
report
peptid
act
wellcharacter
angiotensin
receptor
also
evid
ang
frequent
act
via
dedic
receptor
wide
regard
ma
receptor
ma
g
proteincoupl
receptor
although
ma
express
cardiac
fibroblast
data
shown
mechan
ang
exert
effect
cell
current
unknown
ubiquit
express
multipl
organ
rodent
human
express
particularli
high
human
heart
kidney
testi
heart
found
local
endotheli
cell
smooth
muscl
cell
cardiomyocyt
macrophag
myofibroblast
evid
cardiac
express
activ
regul
preand
posttransl
level
burel
et
al
report
increas
cardiac
mrna
express
activ
infarct
zone
ischem
zone
surround
myocardi
infarct
mi
ishiyama
et
al
show
chang
mrna
level
week
postmi
rat
downregul
cardiac
activ
mrna
level
describ
experiment
heart
failur
rat
week
postmi
decreas
protein
level
measur
week
aortocav
fistula
inconsist
result
model
experiment
heart
failur
suggest
regul
cardiac
express
activ
vari
depend
diseas
state
time
point
measur
obtain
addit
transcript
translat
influenc
also
undergo
posttransl
modif
known
ectodomain
shed
proteas
often
refer
sheddas
releas
ectodomain
solubl
form
vitro
vivo
result
laboratori
indic
process
result
format
major
cleavag
product
retain
roughli
similar
enzymat
activ
disintegrin
metalloproteinas
adam
shown
play
major
role
process
although
recent
find
indic
sheddas
may
involv
rat
develop
ma
becom
detect
birth
increas
express
thereaft
plateau
month
age
ma
exhibit
fairli
broad
tissu
express
profil
includ
heart
kidney
testi
brain
retin
pigment
epithelium
skelet
muscl
liver
adipos
tissu
within
heart
ma
local
vasculatur
cardiomyocyt
fibroblast
detect
qrtpcr
data
shown
although
fibroblast
cell
heart
respond
ang
result
cultur
cell
describ
evid
ma
receptor
arcf
suggest
cell
import
target
strategi
design
enhanc
ang
ma
effect
distinct
substrat
specif
ace
suggest
differ
physiolog
role
enzym
possibl
could
involv
regul
cardiovascular
system
investig
use
genet
engin
mice
gene
transfer
crackow
et
al
report
impair
cardiac
contractil
increas
local
cardiac
ang
ii
level
knockout
mice
cardiac
phenotyp
could
rescu
concomit
delet
ace
gene
although
group
fail
replic
cardiac
phenotyp
report
null
mice
increas
blood
pressur
alter
respons
ang
ii
reduc
cardiac
contractil
increas
cardiac
ang
ii
level
follow
transvers
aortic
constrict
despit
inconsist
total
evid
indic
protect
role
cardiovascular
system
suggest
balanc
ace
may
regul
ang
ii
level
effect
patholog
set
evid
gene
transfer
heart
inhibit
cardiac
remodel
stimul
ang
ii
infus
hypertens
mi
rat
consist
possibl
continu
administr
specif
inhibitor
rat
begin
day
follow
coronari
arteri
ligat
increas
infarct
size
reduc
lv
fraction
shorten
associ
reduct
number
ckit
stem
cell
detect
periinfarct
zone
report
overexpress
heart
caus
cardiac
conduct
disturb
transgen
mice
fibrosi
spontan
hypertens
rat
howev
indic
function
enzym
may
complex
initi
believ
although
administr
ace
inhibitor
angiotensin
receptor
blocker
arb
report
increas
cardiac
mrna
protein
activ
normal
condit
postmi
rat
one
studi
fail
demonstr
signific
effect
ace
inhibit
evid
aldosteron
antagonist
also
increas
protein
level
activ
rat
cardiac
tissu
upregul
mrna
macrophag
heart
failur
patient
result
rais
possibl
least
benefici
effect
report
use
drug
inhibit
ang
ii
gener
andor
cellular
effect
could
relat
increas
express
activ
ma
overexpress
exhibit
constitut
activ
includ
activ
rac
g
q
g
express
physiolog
level
ma
requir
stimul
ang
lesser
extent
angiotensin
peptid
stimul
ma
shown
induc
releas
arachidon
acid
nitric
oxid
upregul
express
latter
suggest
posit
feedback
mechan
part
altern
pathway
ra
interact
ang
ma
also
capabl
alter
signal
pathway
includ
attenu
activ
ang
ii
glucos
serum
augment
activ
bradykinin
overal
receptor
interact
cellular
effect
ang
appear
depend
celltyp
rel
express
level
receptor
signal
intermedi
involv
increas
cardiac
express
protein
level
activ
report
patient
heart
failur
ischem
nonischem
etiolog
hydrolysi
ang
ii
consid
key
pathway
gener
ang
fail
heart
solubl
activ
increas
blood
heart
failur
patient
level
correl
diseas
sever
endogen
inhibitor
inhibitori
autoantibodi
report
exist
plasma
healthi
subject
patient
inflammatori
vasculopathi
respect
given
ace
distinct
even
oppos
effect
metabol
ra
effector
peptid
regul
cardiovascular
structur
function
drug
modifi
balanc
express
activ
enzym
view
potenti
therapeut
tool
treat
varieti
cardiovascular
diseas
tabl
alreadi
describ
ace
inhibitor
arb
aldosteron
antagonist
report
increas
activ
mechan
might
contribut
benefici
effect
cardiac
remodel
thu
provid
addit
rational
use
heart
failur
patient
perspect
arb
would
appear
advantag
sinc
tend
increas
ang
ii
level
effect
along
increas
activ
would
tend
increas
level
protect
peptid
ang
howev
superior
arb
ace
inhibitor
either
mi
survivor
heart
failur
patient
demonstr
recent
hernandezprada
et
al
use
conformationalbas
ration
drug
strategi
identifi
small
molecul
specif
enhanc
activ
one
activ
xanthenon
demonstr
decreas
blood
pressur
improv
cardiac
function
inhibit
cardiac
renal
fibrosi
spontan
hypertens
rat
solubl
recombin
deriv
entir
ectoderm
also
shown
inhibitori
effect
ang
iiinduc
hypertens
mice
thu
agent
addit
ace
inhibitor
arb
aldosteron
antagonist
increas
express
activ
analog
could
novel
therapeut
tool
treat
cardiovascular
diseas
particularli
ang
ii
involv
care
attent
may
howev
necessari
optim
potenti
therapeut
effect
sinc
endogen
inhibitor
autoantibodi
detect
human
plasma
describ
administr
report
result
gener
antibodi
emphas
fact
therapeut
strategi
base
use
design
avoid
enzym
inhibit
result
gener
antibodi
one
addit
potenti
strategi
would
regul
rate
cleavag
surfac
cardiac
cell
retent
enzymat
activ
would
anticip
reduc
ang
ii
increas
ang
within
microenviron
heart
strategi
would
need
account
fact
cleav
singl
site
multipl
enzym
appear
serv
sheddas
process
central
role
howev
suggest
agent
block
activ
could
effect
way
enhanc
activ
heart
although
ang
shown
favor
effect
sever
rat
model
cardiovascular
diseas
includ
attenu
develop
heart
failur
postmi
peptid
limit
pharmacolog
applic
due
rapid
turnov
stabl
ang
analogu
ma
receptor
agonist
could
howev
great
potenti
cardiovascular
therapeut
agent
nonpeptid
ma
agonist
ave
improv
cardiac
function
rat
diabet
isoproterenol
treatment
follow
experimentallyinduc
mi
ave
also
shown
amelior
progress
atherosclerosi
apo
null
mice
anoth
ma
agonist
peptid
report
stabl
ang
extens
studi
agonist
howev
potenti
drawback
sinc
ave
cross
bloodbrain
barrier
could
induc
counterregulatori
central
effect
may
precis
mimic
action
ang
sinc
induc
ca
nitric
oxid
releas
ang
reportedli
ca
independ
knowledg
human
data
exist
regard
ma
agonist
clinic
potenti
well
futur
compound
cardioprotect
agent
recogn
base
consider
explor
effect
stabl
ang
analogu
ma
receptor
agonist
cardiovascular
diseas
clearli
warrant
evid
accumul
target
ang
ma
receptor
might
therapeut
potenti
effect
enhanc
altern
pathway
ra
appear
depend
varieti
factor
includ
approach
taken
specif
condit
time
progress
diseas
state
strategi
enhanc
activ
may
prove
difficult
develop
block
effect
also
pauciti
inform
pathway
involv
ma
signal
interact
receptor
mediat
ang
effect
leav
great
deal
uncertainti
outcom
strategi
design
target
receptor
importantli
howev
fact
effect
newli
develop
reagent
directli
target
ma
receptor
activ
solubl
ma
agonist
tabl
must
compar
drug
current
use
treat
heart
failur
patient
ie
arb
ace
inhibitor
aldosteron
antagonist
determin
target
pathway
alon
target
multipl
compon
ra
offer
advantag
beyond
exist
therapi
unexpect
effect
result
modifi
pathway
potenti
new
therapi
also
care
evalu
certain
advers
side
effect
classic
altern
pathway
renin
angiotensin
system
angiotensin
ii
prefer
substrat
cleav
ctermin
amino
acid
form
heptapeptid
ang
rel
balanc
peptid
could
influenc
rate
progress
cardiac
remodel
develop
heart
failur
